Overview
Human-tissue-driven AI biotech for neurodegenerative diseases.
Details
Verge’s CONVERGE platform uses patient tissue genomics and ML to identify neurodegeneration targets. Lead ALS program in clinical trials.
Human-tissue-driven AI biotech for neurodegenerative diseases. Verge's CONVERGE platform uses patient tissue genomics and ML to identify neurodegeneration targets. Lead ALS program in clinical trials.
Human-tissue-driven AI biotech for neurodegenerative diseases.
Verge’s CONVERGE platform uses patient tissue genomics and ML to identify neurodegeneration targets. Lead ALS program in clinical trials.